CN113347996A - 治疗肿瘤的联用药物组合物 - Google Patents

治疗肿瘤的联用药物组合物 Download PDF

Info

Publication number
CN113347996A
CN113347996A CN202080010713.XA CN202080010713A CN113347996A CN 113347996 A CN113347996 A CN 113347996A CN 202080010713 A CN202080010713 A CN 202080010713A CN 113347996 A CN113347996 A CN 113347996A
Authority
CN
China
Prior art keywords
antibody
seq
pharmaceutical composition
combination
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080010713.XA
Other languages
English (en)
Other versions
CN113347996B (zh
Inventor
张喜全
王训强
杨朝强
樊宇晨
范孟雪
封帆
苏楠
刘瑶
张弛
江海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Nanjing Shunxin Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Nanjing Shunxin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Nanjing Shunxin Pharmaceutical Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113347996A publication Critical patent/CN113347996A/zh
Application granted granted Critical
Publication of CN113347996B publication Critical patent/CN113347996B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

属于生物医药领域，涉及用于治疗胆道系统肿瘤、肝癌、三阴乳腺癌或肺癌的联用药物组合物，其包括抗PD‑L1抗体和安罗替尼，具有良好的抗胆道系统肿瘤、肝癌、三阴乳腺癌或肺癌的活性。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080010713.XA 2019-01-25 2020-01-23 治疗肿瘤的联用药物组合物 Active CN113347996B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2019100713938 2019-01-25
CN201910071392 2019-01-25
CN201910071632 2019-01-25
CN2019100716052 2019-01-25
CN201910071605 2019-01-25
CN2019100713923 2019-01-25
CN201910071632X 2019-01-25
CN201910071393 2019-01-25
PCT/CN2020/073957 WO2020151759A1 (zh) 2019-01-25 2020-01-23 治疗肿瘤的联用药物组合物

Publications (2)

Publication Number Publication Date
CN113347996A true CN113347996A (zh) 2021-09-03
CN113347996B CN113347996B (zh) 2024-04-02

Family

ID=71735577

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010713.XA Active CN113347996B (zh) 2019-01-25 2020-01-23 治疗肿瘤的联用药物组合物

Country Status (8)

Country Link
US (1) US20220089742A1 (zh)
EP (1) EP3915583A4 (zh)
JP (1) JP2022526694A (zh)
KR (1) KR20210120022A (zh)
CN (1) CN113347996B (zh)
AU (1) AU2020212767A1 (zh)
CA (1) CA3127388A1 (zh)
WO (1) WO2020151759A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113893332A (zh) * 2021-11-26 2022-01-07 暨南大学附属第一医院（广州华侨医院） 一种治疗巨块型肝癌的联合药物组合物及其在制备治疗巨块型肝癌药物中的应用
WO2023174408A1 (zh) * 2022-03-18 2023-09-21 正大天晴药业集团南京顺欣制药有限公司 抗tim-3抗体与抗pd-l1抗体的药物组合
WO2023232100A1 (zh) * 2022-06-02 2023-12-07 正大天晴药业集团股份有限公司 用于治疗子宫恶性肿瘤的药物组合

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160700A1 (en) * 2018-07-18 2022-05-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Therapeutic combination of quinoline derivative and antibody
EP4197554A1 (en) * 2020-08-13 2023-06-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined medication for treating soft tissue sarcoma
CN117597146A (zh) * 2021-07-22 2024-02-23 正大天晴药业集团股份有限公司 用于治疗胃癌和/或食管胃结合部癌的联用药物
CN117642181A (zh) * 2021-09-06 2024-03-01 正大天晴药业集团股份有限公司 用于治疗食管癌的药物组合

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118222A1 (en) * 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
US20160108123A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN106255510A (zh) * 2014-03-05 2016-12-21 百时美施贵宝公司 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌
US20170204184A1 (en) * 2014-08-05 2017-07-20 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
CN107530434A (zh) * 2015-04-23 2018-01-02 免疫医疗有限公司 非小细胞肺癌egfr突变阳性的联合疗法
CN107750166A (zh) * 2015-06-16 2018-03-02 默克专利股份有限公司 Pd‑l1 拮抗剂组合治疗
CN108779180A (zh) * 2016-03-23 2018-11-09 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978226A1 (en) * 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118222A1 (en) * 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN106255510A (zh) * 2014-03-05 2016-12-21 百时美施贵宝公司 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌
US20170204184A1 (en) * 2014-08-05 2017-07-20 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
CN107001463A (zh) * 2014-08-05 2017-08-01 中美冠科生物技术（太仓）有限公司 抗pd‑l1抗体
US20160108123A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN107530434A (zh) * 2015-04-23 2018-01-02 免疫医疗有限公司 非小细胞肺癌egfr突变阳性的联合疗法
CN107750166A (zh) * 2015-06-16 2018-03-02 默克专利股份有限公司 Pd‑l1 拮抗剂组合治疗
CN108779180A (zh) * 2016-03-23 2018-11-09 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113893332A (zh) * 2021-11-26 2022-01-07 暨南大学附属第一医院（广州华侨医院） 一种治疗巨块型肝癌的联合药物组合物及其在制备治疗巨块型肝癌药物中的应用
CN113893332B (zh) * 2021-11-26 2024-02-06 暨南大学附属第一医院（广州华侨医院） 一种治疗巨块型肝癌的联合药物组合物及其在制备治疗巨块型肝癌药物中的应用
WO2023174408A1 (zh) * 2022-03-18 2023-09-21 正大天晴药业集团南京顺欣制药有限公司 抗tim-3抗体与抗pd-l1抗体的药物组合
WO2023232100A1 (zh) * 2022-06-02 2023-12-07 正大天晴药业集团股份有限公司 用于治疗子宫恶性肿瘤的药物组合

Also Published As

Publication number Publication date
CA3127388A1 (en) 2020-07-30
JP2022526694A (ja) 2022-05-26
KR20210120022A (ko) 2021-10-06
US20220089742A1 (en) 2022-03-24
WO2020151759A1 (zh) 2020-07-30
EP3915583A4 (en) 2023-01-25
AU2020212767A1 (en) 2021-09-02
CN113347996B (zh) 2024-04-02
EP3915583A1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
CN113347996B (zh) 治疗肿瘤的联用药物组合物
CN113613674A (zh) 治疗小细胞肺癌的联用药物组合物
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN113939315B (zh) 治疗黑色素瘤的联用药物组合物
CN113018429A (zh) 治疗卵巢癌的药物组合
CN113811298A (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
EP4144371A1 (en) Combination drug for treating kidney cancer
CN115698076A (zh) 用于治疗肿瘤的药物
CN115697407A (zh) c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物
CN113766917A (zh) 用于治疗头颈癌的喹啉衍生物
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
CN116036265A (zh) 用于癌症的联用药物
CN117642181A (zh) 用于治疗食管癌的药物组合
CN116209443A (zh) 治疗小细胞肺癌的药物组合
CN116510005A (zh) 治疗肿瘤的联用药物
CN117815387A (zh) Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物
WO2023098798A1 (zh) 用于治疗非小细胞肺癌的药物组合
WO2023232100A1 (zh) 用于治疗子宫恶性肿瘤的药物组合
WO2024051670A1 (zh) 结合tim-3的抗体与结合pd-1的抗体的药物组合
CN116370641A (zh) 用于治疗消化系统恶性肿瘤的联用药物
CN116173198A (zh) 用于肝癌术后辅助治疗的联用药物
EP4197554A1 (en) Combined medication for treating soft tissue sarcoma
CN117085124A (zh) 一种包含抗PD-L1抗体和c-Met激酶抑制剂的药物组合
TW202346342A (zh) 抗tim-3抗體與抗pd-1抗體的藥物組合
CN116437957A (zh) 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant